Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT03182335

Vasopressor SAT Study

To assess the impact of daily awakening from sedation on the amount of vasoactive medication required in the ICU. The hypothesis of this proposal is that the amount of vasoactive drug required to maintain an adequate mean arterial blood pressure will be reduced during a daily awakening from sedation.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Conditions

Low Blood Pressure Cardiovascular Diseases Confusion Critical Illness Delirium Disease Attributes Hypotension Mental Disorders Nervous System Diseases Neurobehavioral Manifestations Neurocognitive Disorders Neurologic Manifestations Pathologic Processes Pathological Conditions, Signs and Symptoms Signs and Symptoms Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

The University of Chicago Medical Center

Chicago, Illinois, 60637, United States

About this study

This observational study will compare mean arterial pressure and vasoactive drug dose recorded at two time points:

  • prior to awakening from sedation
  • during the awakening from sedation trial The vasoactive infusion will be titrated to a mean arterial pressure as determined by the medical team prior to study enrollment. Each enrolled patient will have measurements taken only on the first day of enrollment. Enrolled subjects will also have a delirium assessment using the CAM-ICU tool before the awakening from sedation trial and during the awakening from sedation trial.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • requiring Mechanical ventilation through an endotracheal tube with infusion of sedative or analgesic agent for comfort
  • requiring vasoactive drug via central venous catheter for the treatment of shock

Exclusion criteria

  • patients receiving Dexmedetomidine as sedative

Treatment and study plan

sedation awakening trial

Other

vital signs and delirium assessment (CAM-ICU) at baseline then following routine sedation awakening trial. Patient will thus serve as their own control for these interventions

Other names: SAT

Primary outcomes

  1. change in vasoactive drug dose

    Time frame: baseline thru study completion on average < 4 hrs

    mcg/kg/min baseline dose and nadir dose

Secondary outcomes

  1. change in mean arterial blood pressure

    Time frame: baseline thru study completion on average <4 hrs

    mm Hg

  2. change in prevalence of ICU delirium

    Time frame: baseline thru study completion on average <4hrs

    CAM ICU score

Sponsors and collaborators

Lead sponsor

University of Chicago

Other

Registry information

Official study title

An Assessment of Vasoactive Medication Dose in Mechanically Ventilated Patients Undergoing Daily Sedation Awakening Trial (SAT)

Important dates

Study start
2014
Primary completion
2026
Study completion
2026
First posted
Jun 9, 2017
Registry last updated
Jul 13, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.